3rd Quarter - Report

340B HEALTH for 340B HEALTH

Firm
Client
Income
—
Expenses
$293,586
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

The 340B Drug Pricing Program; S.773 - A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes; H.R.3203 - To enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes; H.R. 853: Closing Loopholes for Orphan Drugs Act; H.R.3: Elijah E. Cummings Lower Drug Costs Now Act; H.R. 4390: PROTECT 340B Act of 2021; S. 2837: 340B Accountability Act of 2021; S. 2814: Vital Medication Affordability Act; H.R. 5463: Drug Pricing Transparency and Accountability Act

LobbyistCovered position, as disclosed
ELISE CRANSTON —
KATHRYN DIBITETTO —
GREG DOGGETT —
KATE ILAHI —
AMANDA SELLERS SMITH —
MAUREEN TESTONI —

Contacted: SENATE; Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 3 (117th), H.R. 4390 (117th), H.R. 5463 (117th), S. 2837 (117th), S. 773 (117th), S. 2814 (117th), H.R. 853 (117th), H.R. 3203 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.